A comprehensive review on electrochemical nano biosensors for precise detection of blood-based oncomarkers in breast cancer
M Sadeghi, S Sadeghi, SM Naghib, HR Garshasbi - Biosensors, 2023 - mdpi.com
Breast cancer (BC), one of the most common and life-threatening cancers, has the highest
incidence rate among women. Early diagnosis of BC oncomarkers is considered the most …
incidence rate among women. Early diagnosis of BC oncomarkers is considered the most …
Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers
Introduction: Immunohistochemistry (IHC) for the estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2) biomarkers has …
receptor (PR), and human epidermal growth factor receptor 2 (HER2) biomarkers has …
Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy
Y Ma, M Zhu, M Lv, P Yuan, X Chen, Z Liu - Cancer Medicine, 2023 - Wiley Online Library
Background The changes in prognostic factors and clinicopathological characteristics of
residual disease following neoadjuvant therapy (NAT) for breast cancer are important …
residual disease following neoadjuvant therapy (NAT) for breast cancer are important …
Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology
R Freitas-Junior, VM de Oliveira, AL Frasson… - BMC cancer, 2022 - Springer
Background Triple-negative breast cancer (TNBC) is a heterogenous subtype involving
different patterns of behavior and clinical course, demanding a complex, individualized …
different patterns of behavior and clinical course, demanding a complex, individualized …
Biomarker dynamics and long-term treatment outcomes in breast cancer patients with residual cancer burden after neoadjuvant therapy
A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is
associated with worse treatment outcomes compared to patients who achieved pathologic …
associated with worse treatment outcomes compared to patients who achieved pathologic …
[HTML][HTML] Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers
Oestrogen receptor (ER)-positive breast cancer (BC) is generally well responsive to
endocrine therapy. Neoadjuvant endocrine therapy (NAET) is increasingly being used for …
endocrine therapy. Neoadjuvant endocrine therapy (NAET) is increasingly being used for …
Use of ultrasound imaging Omics in predicting molecular typing and assessing the risk of postoperative recurrence in breast cancer
X Song, H Xu, X Wang, W Liu, X Leng, Y Hu, Z Luo… - BMC women's …, 2024 - Springer
Background The aim of this study is to assess the efficacy of a multiparametric ultrasound
imaging omics model in predicting the risk of postoperative recurrence and molecular typing …
imaging omics model in predicting the risk of postoperative recurrence and molecular typing …
[HTML][HTML] Changes in Invasive Breast Carcinomas after Neoadjuvant Chemotherapy Can Influence Adjuvant Therapeutic Decisions
BJ Dos Santos, D Balabram, VMR Gomes… - Cancer Research and …, 2024 - ncbi.nlm.nih.gov
Purpose Neoadjuvant chemotherapy (NACT) can change invasive breast carcinomas (IBC)
and influence the patients' overall survival time (OS). We aimed to identify IBC changes after …
and influence the patients' overall survival time (OS). We aimed to identify IBC changes after …
[PDF][PDF] Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET)
Oestrogen receptor (ER)-positive breast cancer (BC) is generally well responsive to
endocrine therapy. Neoadjuvant endocrine therapy (NAET) is increasingly being used for …
endocrine therapy. Neoadjuvant endocrine therapy (NAET) is increasingly being used for …